Safety and Tolerability of Coenzyme Q10 in Hemodialysis Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00908297|
Recruitment Status : Completed
First Posted : May 25, 2009
Last Update Posted : April 24, 2012
|Condition or disease||Intervention/treatment||Phase|
|Cardiovascular Disease End Stage Renal Disease Atherosclerosis Oxidative Stress||Dietary Supplement: Coenzyme Q10||Not Applicable|
There are more than 400,000 patients receiving dialysis in the United States, and we expect that this number will go up. For those on hemodialysis, cardiovascular disease (CVD) accounts for a large part of the health problems that these patients have. Cardiovascular problems come from damage to the heart or blood vessels.
At present, we have no treatments proven to help prevent CVD in those on dialysis. For the general population, we know about many factors that increase the risk of CVD, such as having a high level of "bad" cholesterol. But for people on dialysis, we believe that there are other risk factors that are just as important in the development of CVD.
People on dialysis often have high blood levels of waste products. This is called "uremia". We believe that uremia can set up chemical reactions in the blood which can lead to hardening of the arteries (atherosclerosis), an important part of CVD. Compounds called antioxidants, which stop the chemical reactions, may help prevent CVD.
Coenzyme Q10 is a naturally occurring compound in blood and tissues. It is also a readily available dietary supplement often used as an alternative and complementary medicine. It is a powerful antioxidant. Previous studies have shown that blood levels of coenzyme Q10 are decreased in hemodialysis patients. Because of this, it is important for us to find out if giving coenzyme Q10 to hemodialysis patients can help prevent CVD. However, at present, there are no studies which carefully look at the safety and tolerability of coenzyme Q10, and whether it helps stops the harmful chemical reactions in the blood.
In addition, many people take medications called "statins" to help reduce risk for cardiovascular disease. We know that statins can lower coenzyme Q10. It is important for us to know if hemodialysis patients taking statins have lower levels of coenzyme Q10. It may be that therapy with coenzyme Q10 could increase the beneficial effects of statin therapy in hemodialysis patients.
In this study, we will test to see if different doses of the dietary supplement coenzyme Q10 will be safe and well tolerated in hemodialysis patients. This is with a view to later studies to determine if coenzyme Q10 will help stop harmful chemical reactions in the blood for hemodialysis patients. This study will help us prepare for future studies of coenzyme Q10, by demonstrating the safely and tolerability of this compound in hemodialysis patients.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safety, Tolerability and Efficacy of Coenzyme Q10 in Hemodialysis Patients: Aim 1|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||October 2010|
|Actual Study Completion Date :||November 2010|
- Dietary Supplement: Coenzyme Q10
By mouth (wafer) once daily for duration of study (8 weeks).
Other Name: CoQ10
- 300 mg for two weeks
- 600 mg for two weeks
- 1200 mg for two weeks
- 1800 mg for final two weeks
- Safety Measures: * Laboratory tests on serum: Comprehensive metabolic panel and creatinine phosphokinase. * Electrocardiogram, physical examination findings, and adverse events. [ Time Frame: Every two weeks ]
- Efficacy Measures: Markers in the blood indicating "oxidative stress" [ Time Frame: Every two weeks ]
- Serum biomarkers of Cardiovascular condition and health [ Time Frame: At baseline study visit and last study visit ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00908297
|United States, Washington|
|Northwest Kidney Centers - Scribner|
|Seattle, Washington, United States, 98122|
|Principal Investigator:||Jonathan Himmelfarb, MD||University of Washington - Kidney Research Institute|